Efficacy of Purified Vi Polysaccharide Typhoid Vaccine
Author(s) -
Jong Hwan Park,
Jung Joo Hong,
Eun Sil Choi,
Jinwon Lee,
JaeHak Park
Publication year - 2002
Publication title -
journal of veterinary science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.547
H-Index - 47
eISSN - 1976-555X
pISSN - 1229-845X
DOI - 10.4142/jvs.2002.3.2.67
Subject(s) - typhoid fever , salmonella typhi , typhoid vaccine , titer , western blot , antigen , microbiology and biotechnology , virology , biology , medicine , immunology , virus , escherichia coli , biochemistry , gene
This experiment was conducted to assess the efficacy of typhoid vaccine newly produced by purifying Vi antigen of Salmonella typhi. With Karber method, LD50 of challenging organism (S. typhi ty2) was determined as 6.31 CFU/mouse, and then the organism was used for the study. With Probits method, ED50 of the vaccine was determined as 0.016 microg / 0.5 ml / mouse. The ELISA titer (0.5097+/-0.0606) was 4 times in the group treated with high dose (0.25 microg/0.5ml) as in control (0.1113+/-0.0110). Six major protein bands of 66, 55, 35, 33, 18, and 9 kd were detected in Western blot analysis with serum of a vaccine treated mouse, whereas only one weak band of about 35 kd was detected with serum of a control mouse. We concluded that typhoid vaccine produced by purifying Vi antigen of S. typhi very effectively prevent S. typhi infection in mice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom